Yesterday, Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, held its 2009 Annual Meeting of Shareholders in Knoxville, Tennessee. During the meeting, shareholders voted to re-elect the companyâ€™s five members of the Board of Directors, which is composed of three inside directors, and two outside directors. Each Director serves a one-year term.
Dr. Dees, CEO of Provectus commented, â€œWe appreciate the confidence of our shareholders as Provectus continues to achieve its milestones for the development of PV-10 and PH-10. Our recently reported ASCO data support our mission to continue our quest to find a viable, safe and effective treatment for metastatic melanoma, and further our research towards that end. Having completed patient accrual in May for our phase 2 melanoma trial, we look forward to communicating additional results to the scientific community and investors in coming months.â€
Dr. Dees continued, â€œWhile our primary focus has been directed towards gaining regulatory approval for PV-10 in metastatic melanoma, data from oncology tests in animals indicates the drug has broad spectrum activity towards numerous tumor types. Further, to our knowledge PV-10 is the only intralesionally delivered agent that has been repeatedly demonstrated to induce removal of remote, untreated tumors through a bystander effect.â€
Dr. Dees concluded, â€œWhile our focus has been on developing PV-10 for metastatic melanoma, our scientific team and investigators are also working on developing PV-10 for other primary and metastatic cancers, such as those of the liver, as well as on PH-10 for atopic dermatitis and psoriasis, both of which are in Phase 2 trials. We look forward to furthering these important studies as well in the upcoming year.â€
Provectus also announced that it has updated its website, providing investors and the scientific community with an easy-to-navigate portal to get up-to-date information on the company and its clinical trials. The improved and highly-functional website enables the public to get information they need on Provectus and its development pipeline.